Abstract Library

#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells

Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Klomp I, van Koetsveld P, Dogan-Oruç F, de Herder W,

Keywords: somatostatin type 2 receptor, BON-1, GOT-1, upregulation, DNA methyltransferase inhibitor, histone deacetylase inhibitor, epigenetic,

#1870 Detection of Metastatic Insulinoma with 68Ga-NODAGA-Exendin-4 PET/CT in a Young Child – A Case Report

Introduction: Malignant insulinomas are extremely rare in children. Localizing metastases of insulinoma is challenging. Imaging modalities like CT and MRI show limited results. Somatostatin-receptor (SSTR) imaging (SRS) performs better. However, a subgroup of malignant insulinoma lack SSRT-2 and can, therefore, not be localized using SRS. We propose that in these cases GLP-1R imaging, using the stable GLP-1 analog exendin, could play an important role.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Boss M

Authors: Boss M, de Herder W, Hussain K, Shah P, Brom M,

Keywords: Metastatic insulinoma, GLP-1R, PET, exendin,

#1858 Quality of Life in Patients with Multiple Endocrine Neoplasia Type I (MEN1): Results from the Dutch MEN1 Study Group

Introduction: Multiple Endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome, characterized by an increased lifetime risk of benign and malignant endocrine tumors in various organs. Data on quality of life (QoL) in patients with MEN1 are scarce, whereas QoL is considered an important treatment outcome.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Van Leeuwaarde R

Authors: Van Leeuwaarde R, Beijers H, de Herder W, Dekkers O, Van der Horst-Schrivers A,

Keywords: MEN1, QoL,

#1807 Adherence to WHO2010 Guideline for Diagnosis of Neuroendocrine Carcinoma and Prognostic Significance

Introduction: Neuroendocrine carcinoma’s (NEC) are diagnosed by a combination of immunohistochemistry (IHC) and morphology according to the 2010 WHO guidelines.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Zandee W, Van der Zwan J, de Herder W, Van Velthuysen L,

Keywords: neuroendocrine carcinoma, IHC, morphology, diagnosis, prognosis, who 2010 ,

#1765 Management of MEN1 Related Non-Functioning Pancreatic NETs: A Shifting Paradigm. Results from the Dutch MEN1 Study Group

Introduction: The evidence base when to operate MEN1 related non-functioning pancreatic neuroendocrine tumors (NF-pNETs) is meager.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nell S

Authors: Nell S, Verkooijen H, Pieterman C, de Herder W, Hermus A,

Keywords: MEN1,